Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-label, Phase 3 Study of Acalabrutinib in Combination With Rituximab and Reduced Dose CHOP (R-miniCHOP) in OldEr Adults With Untreated Diffuse Large B-Cell Lymphoma

NCT05820841 is registered in ClinicalTrials.gov with Universität des Saarlandes as lead sponsor.

NCT NCT05820841
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05820841 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-label, Phase 3 Study of Acalabrutinib in Combination With Rituximab and Reduced Dose CHOP (R-miniCHOP) in OldEr Adults With Untreated Diffuse Large B-Cell Lymphoma
Lead sponsor
Universität des Saarlandes
Phase
Phase 3
Overall status
Recruiting
Start date
June 7, 2023
Completion date
February 28, 2029
Enrollment
330 (estimated)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b cell lymphoma, large b-cell lymphoma